These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 34324311)

  • 1. Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker Controversy.
    Ibrahim S; Lan C; Chabot C; Mitsa G; Buchanan M; Aguilar-Mahecha A; Elchebly M; Poetz O; Spatz A; Basik M; Batist G; Zahedi RP; Borchers CH
    Anal Chem; 2021 Aug; 93(31):10816-10824. PubMed ID: 34324311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110α in cell lines and tumor tissues.
    Froehlich BC; Popp R; Sobsey CA; Ibrahim S; LeBlanc A; Mohammed Y; Buchanan M; Aguilar-Mahecha A; Pötz O; Chen MX; Spatz A; Basik M; Batist G; Zahedi RP; Borchers CH
    Analyst; 2021 Oct; 146(21):6566-6575. PubMed ID: 34585690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A robust immunohistochemical assay for detecting PTEN expression in human tumors.
    Sangale Z; Prass C; Carlson A; Tikishvili E; Degrado J; Lanchbury J; Stone S
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):173-83. PubMed ID: 20930614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
    Wang LL; Hao S; Zhang S; Guo LJ; Hu CY; Zhang G; Gao B; Zhao JJ; Jiang Y; Tian WG; Wang J; Luo DL
    Hum Pathol; 2017 Mar; 61():49-57. PubMed ID: 27864123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.
    Capodanno A; Camerini A; Orlandini C; Baldini E; Resta ML; Bevilacqua G; Collecchi P
    Hum Pathol; 2009 Oct; 40(10):1408-17. PubMed ID: 19428048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT and PTEN as potential prognostic markers in breast cancer.
    Neto JC; Ikoma MM; Carvalho KC; Vassallo J; De Brot M; Gobbi H; Soares FA; Rocha RM
    Exp Mol Pathol; 2012 Feb; 92(1):20-6. PubMed ID: 22019339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Application of Multiple Reaction Monitoring-Mass Spectrometry to Human Epidermal Growth Factor Receptor 2 Measurements as a Potential Diagnostic Tool for Breast Cancer Therapy.
    Do M; Kim H; Yeo I; Lee J; Park IA; Ryu HS; Kim Y
    Clin Chem; 2020 Oct; 66(10):1339-1348. PubMed ID: 33001186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors.
    Popp R; Li H; LeBlanc A; Mohammed Y; Aguilar-Mahecha A; Chambers AG; Lan C; Poetz O; Basik M; Batist G; Borchers CH
    Anal Chem; 2017 Oct; 89(19):10592-10600. PubMed ID: 28853539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.
    Sakr RA; Barbashina V; Morrogh M; Chandarlapaty S; Andrade VP; Arroyo CD; Olvera N; King TA
    Appl Immunohistochem Mol Morphol; 2010 Jul; 18(4):371-4. PubMed ID: 20216404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
    Okutur K; Bassulu N; Dalar L; Aydin K; Bozkurt M; Pilanci KN; Dogusoy GB; Tecimer C; Mandel NM; Demir G
    Asian Pac J Cancer Prev; 2015; 16(7):2645-51. PubMed ID: 25854340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.
    De Marchi T; Kuhn E; Dekker LJ; Stingl C; Braakman RB; Opdam M; Linn SC; Sweep FC; Span PN; Luider TM; Foekens JA; Martens JW; Carr SA; Umar A
    J Proteome Res; 2016 Apr; 15(4):1230-42. PubMed ID: 26958999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity.
    Ágoston EI; Micsik T; Ács B; Fekete K; Hahn O; Baranyai Z; Dede K; Bodoky G; Bursics A; Kulka J; Krenács T; Győrffy B; Harsányi L; Szász AM
    Diagn Pathol; 2016 Jul; 11(1):61. PubMed ID: 27392434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
    Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
    Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN regulates phospholipase D and phospholipase C.
    Alvarez-Breckenridge CA; Waite KA; Eng C
    Hum Mol Genet; 2007 May; 16(10):1157-63. PubMed ID: 17405772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical assessment of PTEN in vulvar cancer: best practices for tissue staining, evaluation, and clinical association.
    Lavorato-Rocha AM; Anjos LG; Cunha IW; Vassallo J; Soares FA; Rocha RM
    Methods; 2015 May; 77-78():20-4. PubMed ID: 25562748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
    DeGraffenried LA; Fulcher L; Friedrichs WE; Grünwald V; Ray RB; Hidalgo M
    Ann Oncol; 2004 Oct; 15(10):1510-6. PubMed ID: 15367412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.
    Zhou K; Zhang T; Fan Y; Serick ; Du G; Wu P; Geng D
    Tumour Biol; 2016 Oct; 37(10):13469-13477. PubMed ID: 27465551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
    Tekesin K; Emin Gunes M; Bayrak S; Akar E; Ozturk T; Altinay S; Tural D
    J BUON; 2019; 24(5):1920-1926. PubMed ID: 31786856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
    Li X; Zhang R; Liu Z; Li S; Xu H
    Oncotarget; 2017 Mar; 8(12):20252-20265. PubMed ID: 28423632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.